These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17644021)

  • 1. Iron chelation, quo vadis?
    Nick H
    Curr Opin Chem Biol; 2007 Aug; 11(4):419-23. PubMed ID: 17644021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferasirox: for iron overload: only a third-line option.
    Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17929382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox Novartis.
    Barton JC
    Curr Opin Investig Drugs; 2005 Mar; 6(3):327-35. PubMed ID: 15816510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
    Liu J; Obando D; Schipanski LG; Groebler LK; Witting PK; Kalinowski DS; Richardson DR; Codd R
    J Med Chem; 2010 Feb; 53(3):1370-82. PubMed ID: 20041672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
    Di Tucci AA; Murru R; Alberti D; Rabault B; Deplano S; Angelucci E
    Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron-chelating therapy.
    Hershko C; Weatherall DJ
    Crit Rev Clin Lab Sci; 1988; 26(4):303-45. PubMed ID: 3077034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concepts and goals in the management of transfusional iron overload.
    Porter JB
    Am J Hematol; 2007 Dec; 82(12 Suppl):1136-9. PubMed ID: 17968973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
    Kontoghiorghes GJ; Pattichis K; Neocleous K; Kolnagou A
    Curr Med Chem; 2004 Aug; 11(16):2161-83. PubMed ID: 15279556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future therapy in haemochromatosis and Wilson's disease.
    Murray KF; Lam D; Kowdley KV
    Expert Opin Pharmacother; 2003 Dec; 4(12):2239-51. PubMed ID: 14640923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of iron overload in thalassemia.
    Cianciulli P
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD; Evans RW; Evans PJ; Hider RC
    Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.
    Kontoghiorghes GJ
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic and natural iron chelators: therapeutic potential and clinical use.
    Hatcher HC; Singh RN; Torti FM; Torti SV
    Future Med Chem; 2009 Dec; 1(9):1643-70. PubMed ID: 21425984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New orally active alpha-ketohydroxy pyridine chelators for the treatment of iron overload.
    Kontoghiorghes GJ
    Birth Defects Orig Artic Ser; 1988; 23(5B):97-103. PubMed ID: 3390580
    [No Abstract]   [Full Text] [Related]  

  • 15. The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug.
    Graziano JH; Grady RW; Cerami A
    J Pharmacol Exp Ther; 1974 Sep; 190(3):570-5. PubMed ID: 4416298
    [No Abstract]   [Full Text] [Related]  

  • 16. PCTH: a novel orally active chelator for the treatment of iron overload disease.
    Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR
    Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral iron chelators: new opportunities and new dilemmas.
    Hershko C
    Haematologica; 2006 Oct; 91(10):1307-12. PubMed ID: 17018378
    [No Abstract]   [Full Text] [Related]  

  • 18. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
    Lim CK; Kalinowski DS; Richardson DR
    Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
    Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron binding dendrimers: a novel approach for the treatment of haemochromatosis.
    Zhou T; Neubert H; Liu DY; Liu ZD; Ma YM; Kong XL; Luo W; Mark S; Hider RC
    J Med Chem; 2006 Jul; 49(14):4171-82. PubMed ID: 16821777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.